|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2006-9-22
|
|
pubmed:abstractText |
The immune suppression caused by HIV infection accelerates the course of liver disease caused by chronic hepatitis B virus (HBV) infection. We assessed the outcome of HIV/HBV-coinfected patients exposed to highly active antiretroviral therapy (HAART) including anti-HBV active drugs. Baseline and follow-up plasma HBVDNA and HIV-RNA levels, HBV serological markers, and CD4 counts were longitudinally evaluated in all HBsAg(+) individuals with HIV infection on regular follow-up at an urban HIV reference clinic. Out of 79 HBsAg(+) chronic carriers identified, 39 (50%) were HBeAg(+). Lamivudine (3TC) alone had been received by 37% of patients, while 3TC plus tenofovir (concomitantly or consecutively) had been taken by 58% of them. The median follow-up was of 52 months. Loss of HBeAg or HBsAg occurred in 28% (10/36) and 13% (10/75) of patients, respectively. In multivariate analysis, only undetectable plasma HIV-RNA levels [OR 4.58 (95% CI 1.25-16.78); p = 0.02] and greater CD4 gains on HAART [OR 1.003 (95% CI 1.000-1.006); p = 0.03] were associated with undetectable serum HBV-DNA at the end of follow-up. Anti-HBV active HAART makes it possible to achieve HBsAg clearance, anti-HBe seroconversion, and suppression of HBV replication in a substantial proportion of HBV/HIV-coinfected patients, particularly in those with complete HIV suppression and greater immune recovery. Thus, HBV/HIV-coinfected patients might benefit from an earlier introduction of HAART.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adenine,
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Retroviral Agents,
http://linkedlifedata.com/resource/pubmed/chemical/DNA, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/Hepatitis B Surface Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/Hepatitis B e Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/Lamivudine,
http://linkedlifedata.com/resource/pubmed/chemical/Phosphonic Acids,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/tenofovir disoproxil
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0889-2229
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
22
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
842-8
|
|
pubmed:meshHeading |
pubmed-meshheading:16989608-Adenine,
pubmed-meshheading:16989608-Adult,
pubmed-meshheading:16989608-Anti-Retroviral Agents,
pubmed-meshheading:16989608-Antiretroviral Therapy, Highly Active,
pubmed-meshheading:16989608-Chi-Square Distribution,
pubmed-meshheading:16989608-DNA, Viral,
pubmed-meshheading:16989608-Drug Resistance, Viral,
pubmed-meshheading:16989608-Drug Therapy, Combination,
pubmed-meshheading:16989608-Female,
pubmed-meshheading:16989608-Follow-Up Studies,
pubmed-meshheading:16989608-HIV Infections,
pubmed-meshheading:16989608-Hepatitis B, Chronic,
pubmed-meshheading:16989608-Hepatitis B Surface Antigens,
pubmed-meshheading:16989608-Hepatitis B e Antigens,
pubmed-meshheading:16989608-Hepatitis B virus,
pubmed-meshheading:16989608-Humans,
pubmed-meshheading:16989608-Lamivudine,
pubmed-meshheading:16989608-Male,
pubmed-meshheading:16989608-Phosphonic Acids,
pubmed-meshheading:16989608-RNA, Viral,
pubmed-meshheading:16989608-Regression Analysis,
pubmed-meshheading:16989608-Statistics, Nonparametric,
pubmed-meshheading:16989608-Treatment Outcome
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Virological outcome of chronic hepatitis B virus infection in HIV-coinfected patients receiving anti-HBV active antiretroviral therapy.
|
|
pubmed:affiliation |
Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain. m_nunez_g@hotmail.com
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
